RESULTS:
Eight healthy volunteers participated in this Phase I study assessing the safety of AAT. No patients experienced an adverse or unanticipated event related to their participation in this study. AAT implants were well-tolerated and demonstrated satisfactory participant comfort and physician ease-of-use ratings. Additionally, we evaluated immune profiles of AAT using flow cytometry to quantify the presence of T cells, B cells, dendritic cells, macrophages, M1-polarized (inflammatory) macrophages, and M2-polarized (wound-healing) macrophages. Our preliminary results indicate that AAT is associated with pro-regenerative immune responses, including M2 macrophage polarization and increased IL-4 expression.
CONCLUSION:
AAT is a new soft tissue reconstruction material showing promising results in this Phase I study for safe use in humans. Further studies, including a Phase II trial, are necessary to determine efficacy in humans. 
PURPOSE:
Tissue engineering seeks to develop physiologically appropriate tissues to restore, maintain or improve function in clinical contexts, and provide platforms with which to study basic biological processes and screen drug candidates and delivery strategies. The complete realization of these goals will represent a paradigm shift. In medicine, it will reduce the use of patient tissue and the associated morbidity at donor sites; in drug development, it will improve the economics and efficacy of early stage drug screening and replace animal testing with appropriate human tissues. We have pioneered approaches to form microvascular networks within 3-D tissue scaffolds. Despite our successes, the overall field has suffered from the lack of a complete suite of tools with which to control these complex cultures with respect to both physical and biological parameters and make them compatible with microsurgery. Here we present an autonomous tissue cartridge (ATC) for recapitulation of the microvasculature in vitro which solves these problems on three fronts: 1) Precise control of flows within vessels, which can perfuse the microvascular networks with nanoliter-precision control. 2) Hardware that enables fluidic, thermal and gas-phase (O 2 , CO 2 , H 2 O) control of culture parameters in a compact, portable and versatile benchtop platform. Importantly, this platform eliminates the need for conventional incubators and provides live fluorescence imaging during long-term cultures 3) Scaffolding procedures that enable microsurgical anastomosis of an endothelialized vessel within a 3-D matrix in an animal model. Results from the system that study the effect of hemodynamic forces on vascular cells provide new biological insights.
METHODS:
Microvessel tissue templates were constructed in Type I collagen using soft lithography and seeded with human umbilical vein endothelial cells. The fully assembled microfluidic tissue culture device with enclosed microvessels was cultured in the benchtop system with live imaging for 3-7 days under pump-driven flow using a range of flow rates to achieve physiologic shear stress against the vessel walls, (0.5 Pa, 1.5 Pa, 2.5 Pa). Cell morphology, alignment and migration were analyzed.
RESULTS:
The ATC provided consistently stable environmental and temperature control throughout extended cultures. Live imaging revealed dynamic endothelia with cells migrating throughout the vessel walls, both downstream (with) and upstream (against) the flow direction. Cell-cell junctions were contiguous, indicating a confluent, healthy endothelium with intact cytoskeletons. The cross-sectional area of the microvessel expanded and changed profile from the original square cross-section defined lithographically toward an elliptical cross-section with a larger dimension. The displacement of migrating endothelial cells correlated positively with the applied shear stress, with maximum displacement occurring at the highest shear 2.5 Pa (25 dyne/ cm 2 ). Similarly, the endothelial cells elongated and aligned in the direction of flow, with net alignment increasing with the magnitude of shear.
CONCLUSIONS:
This breakthrough sets the stage for clinical translation of the pre-vascularized tissues, provides new insights into relationships between hemodynamic forces and cell morphology/dynamics, and advances studies of mechano-biology that seek to identify the molecular mechanisms by which endothelial cells sense shear stress. 
Optimizing Vascular Invasion into Hydrogel Scaffolds Using Bioactive Sphingolipids

PURPOSE:
The promise of an ideal "off-the-shelf " regenerative template has long been predicated upon the availability of an adequate inherent vasculature. Due to this, current dermal regenerative templates such as Integra™ are clinically limited in scope secondary to their dependence on excellent host wound bed vascularity. This reliance in turn restricts their applicability in any but the most optimal wound beds, all but prohibiting their use in wound beds with exposed bone, tendon, or hardware. Recently, sphingosine-1-phosphate (S1P), a bioactive sphingolipid stored in platelets and found in micromolar quantities in the plasma and nearly absent in the interstitium, has gained widespread attention for its effects on endothelial motility and vascular maturation. In fact, it is thought that a reversal of the physiologic gradient causing S1P to be present in the interstitium, such as in wound healing, is responsible for inducing reparative angiogenesis. It is further hypothesized that gradients of S1P are a major signaling component in activating homeostatically nascent angiogenic mechanisms by promoting endothelial sprouting, motility, and stability. Herein we build upon our novel scaffolds by incorporating a bioactive sphingolipid into a collagen matrix in order to select for and amplify endothelial invasion to create a rapidly integrated, vascularized, tissue engineered construct with potentially profound implications for application in poorly vascularized wound beds.
METHODS:
Raft cultures were created by seeding 100 ul of 3 mg/ml type I collagen onto 8um pore rafts. GFP labeled HUVECs were topically seeded and cultured for 7 days. The media in contact with the cells was devoid of S1P and a gradient in the collagen established by filling the bottom well in 1uM S1P. Gradients of VEGF, FGF, and concentrations of fetal bovine serum were also tested in the absence of S1P. Rafts were cross-sectioned at 100 um using a vibratome and sections stained with toluidine blue. Sections were quantified for number of sprouts per square micron, average length of sprouts, number of cells per structure, and number of junctions. Confocal reflectance z-stacks were taken to confirm the presence of lumens within the sprouts.
RESULTS:
Robust and complex invasion was seen as early as day 3 in cultures containing S1P. S1P rafts demonstrated multicellular, luminal, complex sprouts that anastomosed to adjacent sprouts as early as day 14. At seven days of culture, these constructs exhibited an average sprout density of 37 ± 8 sprouts/mm2 with an average depth of invasion of 129 ± 58 um. Origin endoluminal diameters were on the order of 10-20 um. Rafts without S1P exhibited confluent superficial growth but no invasion into the collagen matrix regardless of VEGF, FGF, or serum gradient.
CONCLUSION:
With current dermal replacement products currently limited by an inadequate induction of endothelial invasion in poorly vascularized wound beds, we have herein demonstrated the remarkable ability of sphingosine-1-phosphate, a bioactive sphingolipid, to induce robust and
